Dr. Juárez Soto on the Rationale to Analyze the Latin American Subgroup of the TITAN Trial in mHSPC
May 26th 2021Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.
Read More